Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRH03S
|
|||
| Drug Name |
Tarlatamab
|
|||
| Synonyms |
AMG757
Click to Show/Hide
|
|||
| Drug Type |
Bispecific T-cell engager
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Delta-like protein 3 (DLL3) | Target Info | . | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [2] | |
| KEGG Pathway | Endocrine resistance | |||
| Notch signaling pathway | ||||
| Th1 and Th2 cell differentiation | ||||
| Pathways in cancer | ||||
| Breast cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05060016) A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301). U.S.National Institutes of Health. | |||
| REF 2 | Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.